Lenalidomide based triplets in relapsed/refractory multiple
myeloma: analysis of the Czech Myeloma Group

J 2025

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group

MINARIK, Jiri; Luděk POUR; Vojtech LATAL; Tomas JELINEK; Jan STRAUB et al.

Základní údaje

Originální název

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group

Autoři

Vydání

BMC Cancer, London, BioMed Central, 2025, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143775

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Multiple myeloma; Relapsed/refractory; Lenalidomide triplets; Risk groups

Štítky

14110212, rivok

Příznaky

Recenzováno

Změněno: 24. 2. 2026 12:39, Mgr. Tereza Miškechová

Anotace

V originále

Despite significant advancements in therapy of multiple myeloma (MM) over the past 20 years, most patients experience relapse, necessitating new treatment approaches. This study aims to compare the real-world effectiveness of lenalidomide (LEN)-based triplet therapies, specifically daratumumab (DRD), carfilzomib (KRD), and ixazomib (IRD), in relapsed/refractory multiple myeloma (RRMM).A retrospective registry-based study analyzed 538 RRMM patients undergoing therapy for their first to third relapse. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), with a matching-adjusted indirect comparisons (MAIC) employed to address cohort differences.ORR was highest for DRD at 91.4%, followed by KRD (89.6%) and IRD cohorts (Early-IRD: 79.6%, Late-IRD: 70.8%). Median PFS for DRD was greater at 23.64 months compared to KRD (16.52 months) and IRD groups (Early-IRD: 19.97 months, Late-IRD: 11.57 months). The MAIC confirmed better outcomes for the DRD regimen. High-risk features were not overcome by any of the LEN-based regimens.The findings underscore the superior efficacy of DRD in achieving sustained responses in RRMM patients. The composition of the cohort is a crucial factor, extending beyond selection criteria. This study highlights the importance of real-world evidence in assessing treatment modalities in clinical settings.

Návaznosti

EH22_008/0004644, projekt VaV

Název: Záchrana životů prostřednictvím výzkumu v oblasti včasné detekce a prevence rakoviny: Molekulární, genomické a sociální faktory

Citovat

MINARIK, Jiri; Luděk POUR; Vojtech LATAL; Tomas JELINEK; Jan STRAUB; Alexandra JUNGOVA; Jakub RADOCHA; Petr PAVLICEK; Martin ŠTORK; Tomas PIKA; Petra KRHOVSKA; Tereza POPKOVA; Frantisek SEDLAK; Ivan SPICKA; Pavel JINDRA; Vladimira CAPOUNOVA; Vladimir MAISNAR a Roman HAJEK. Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group. BMC Cancer. London: BioMed Central, 2025, roč. 25, č. 1, s. 1-11. ISSN 1471-2407. Dostupné z: https://doi.org/10.1186/s12885-025-14087-y.

@article{2556440,
   author = {Minarik, Jiri and Pour, Luděk and Latal, Vojtech and Jelinek, Tomas and Straub, Jan and Jungova, Alexandra and Radocha, Jakub and Pavlicek, Petr and Štork, Martin and Pika, Tomas and Krhovska, Petra and Popkova, Tereza and Sedlak, Frantisek and Spicka, Ivan and Jindra, Pavel and Capounova, Vladimira and Maisnar, Vladimir and Hajek, Roman},
   article_location = {London},
   article_number = {1},
   doi = {https://doi.org/10.1186/s12885-025-14087-y},
   keywords = {Multiple myeloma; Relapsed/refractory; Lenalidomide triplets; Risk groups},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group},
   url = {https://link.springer.com/article/10.1186/s12885-025-14087-y},
   volume = {25},
   year = {2025}
}

TY  - JOUR
ID  - 2556440
AU  - Minarik, Jiri - Pour, Luděk - Latal, Vojtech - Jelinek, Tomas - Straub, Jan - Jungova, Alexandra - Radocha, Jakub - Pavlicek, Petr - Štork, Martin - Pika, Tomas - Krhovska, Petra - Popkova, Tereza - Sedlak, Frantisek - Spicka, Ivan - Jindra, Pavel - Capounova, Vladimira - Maisnar, Vladimir - Hajek, Roman
PY  - 2025
TI  - Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
JF  - BMC Cancer
VL  - 25
IS  - 1
SP  - 1-11
EP  - 1-11
PB  - BioMed Central
SN  - 14712407
KW  - Multiple myeloma
KW  - Relapsed/refractory
KW  - Lenalidomide triplets
KW  - Risk groups
UR  - https://link.springer.com/article/10.1186/s12885-025-14087-y
N2  - Despite significant advancements in therapy of multiple myeloma (MM) over the past 20 years, most patients experience relapse, necessitating new treatment approaches. This study aims to compare the real-world effectiveness of lenalidomide (LEN)-based triplet therapies, specifically daratumumab (DRD), carfilzomib (KRD), and ixazomib (IRD), in relapsed/refractory multiple myeloma (RRMM).A retrospective registry-based study analyzed 538 RRMM patients undergoing therapy for their first to third relapse. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), with a matching-adjusted indirect comparisons (MAIC) employed to address cohort differences.ORR was highest for DRD at 91.4%, followed by KRD (89.6%) and IRD cohorts (Early-IRD: 79.6%, Late-IRD: 70.8%). Median PFS for DRD was greater at 23.64 months compared to KRD (16.52 months) and IRD groups (Early-IRD: 19.97 months, Late-IRD: 11.57 months). The MAIC confirmed better outcomes for the DRD regimen. High-risk features were not overcome by any of the LEN-based regimens.The findings underscore the superior efficacy of DRD in achieving sustained responses in RRMM patients. The composition of the cohort is a crucial factor, extending beyond selection criteria. This study highlights the importance of real-world evidence in assessing treatment modalities in clinical settings.
ER  -

MINARIK, Jiri; Luděk POUR; Vojtech LATAL; Tomas JELINEK; Jan STRAUB; Alexandra JUNGOVA; Jakub RADOCHA; Petr PAVLICEK; Martin ŠTORK; Tomas PIKA; Petra KRHOVSKA; Tereza POPKOVA; Frantisek SEDLAK; Ivan SPICKA; Pavel JINDRA; Vladimira CAPOUNOVA; Vladimir MAISNAR a Roman HAJEK. Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group. \textit{BMC Cancer}. London: BioMed Central, 2025, roč.~25, č.~1, s.~1-11. ISSN~1471-2407. Dostupné z: https://doi.org/10.1186/s12885-025-14087-y.

Přehled o publikaci